Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Top Cited Papers
- 23 October 2003
- Vol. 327 (7421) , 951-3
- https://doi.org/10.1136/bmj.327.7421.951
Abstract
Objective To assess the effectiveness of metformin in improving clinical and biochemical features of polycystic ovary syndrome. Design Systematic review and meta-analysis. Data sources Randomised controlled trials that investigated the effect of metformin compared with either placebo or no treatment, or compared with an ovulation induction agent. Selection of studies 13 trials were included for analysis, including 543 women with polycystic ovary syndrome that was defined by using biochemical or ultrasound evidence. Main outcome measure Pregnancy and ovulation rates. Secondary outcomes of clinical and biochemical features of polycystic ovary syndrome. Results Meta-analysis showed that metformin is effective in achieving ovulation in women with polycystic ovary syndrome, with odds ratios of 3.88 (95% confidence interval 2.25 to 6.69) for metformin compared with placebo and 4.41 (2.37 to 8.22) for metformin and clomifene compared with clomifene alone. An analysis of pregnancy rates shows a significant treatment effect for metformin and clomifene (odds ratio 4.40, 1.96 to 9.85). Metformin has an effect in reducing fasting insulin concentrations, blood pressure, and low density lipoprotein cholesterol. We found no evidence of any effect on body mass index or waist:hip ratio. Metformin was associated with a higher incidence of nausea, vomiting, and other gastrointestinal disturbance. Conclusions Metformin is an effective treatment for anovulation in women with polycystic ovary syndrome. Its choice as a first line agent seems justified, and there is some evidence of benefit on variables of the metabolic syndrome. No data are available regarding the safety of metformin in long term use in young women and only limited data on its safety in early pregnancy. It should be used as an adjuvant to general lifestyle improvements and not as a replacement for increased exercise and improved diet.Keywords
This publication has 38 references indexed in Scilit:
- Contraindications to use of metforminBMJ, 2003
- Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practiceBritish Journal of Clinical Pharmacology, 2002
- Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled TrialJournal of Clinical Endocrinology & Metabolism, 2002
- Insulin Reduction with Metformin Increases Luteal Phase Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein 1 Concentrations and Enhances Uterine Vascularity and Blood Flow in the Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 2001
- Metformin and the Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 2001
- Effect of Long-Term Treatment with Metformin Added to Hypocaloric Diet on Body Composition, Fat Distribution, and Androgen and Insulin Levels in Abdominally Obese Women with and without the Polycystic Ovary SyndromeJournal of Clinical Endocrinology & Metabolism, 2000
- Polycystic ovaries and associated clinical and biochemical features in young womenClinical Endocrinology, 1999
- Syndrome XDrugs, 1999
- Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary SyndromeNew England Journal of Medicine, 1996
- Higher multiple births and the modern management of infertility in Britain. For the British Association of Perinatal MedicineBJOG: An International Journal of Obstetrics and Gynaecology, 1992